Shots: The P-III ATLANTIS study involves assessing Zepzelca (lurbinectedin, 2.0mg/m2) + doxorubicin vs topotecan/ CAV in 613 adult patients in a ratio (1:1) aged ≥18yrs. with SCLC whose disease progressed […]readmore
Tags : Zepzelca
The US FDA has approved multiple NDAs and BLAs in Jun 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and […]readmore
Shots: The approval is based on P-II assessing Zepzelca in 105 adults Ultragenyx with SCLC at 26 hospitals in the US and EU The study resulted in ORR was 35%, median […]readmore